These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22232540)

  • 1. Transformative mutation specific pharmacotherapy for cystic fibrosis.
    Sanders DB; Farrell PM
    BMJ; 2012 Jan; 344():e79. PubMed ID: 22232540
    [No Abstract]   [Full Text] [Related]  

  • 2. Ivacaftor in a G551D homozygote with cystic fibrosis.
    Harrison MJ; Murphy DM; Plant BJ
    N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763
    [No Abstract]   [Full Text] [Related]  

  • 3. Ivacaftor for cystic fibrosis.
    Barry PJ; Donaldson AL; Jones AM
    BMJ; 2018 May; 361():k1783. PubMed ID: 29773589
    [No Abstract]   [Full Text] [Related]  

  • 4. CT imaging of pediatric patients with cystic fibrosis on ivacaftor therapy.
    Hayes D; Long FR; McCoy KS; Sheikh SI
    Lung; 2014 Oct; 192(5):823-4. PubMed ID: 25099273
    [No Abstract]   [Full Text] [Related]  

  • 5. Lung clearance index response in patients with CF with class III CFTR mutations.
    Kane M; Gonska T; Jensen R; Avolio J; Klingel M; Stanojevic S; Ratjen F
    Thorax; 2016 May; 71(5):476-7. PubMed ID: 26944510
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting the basic defect in cystic fibrosis.
    Welsh MJ
    N Engl J Med; 2010 Nov; 363(21):2056-7. PubMed ID: 21083391
    [No Abstract]   [Full Text] [Related]  

  • 7. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
    van Koningsbruggen-Rietschel S; Naehrlich L
    Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
    [No Abstract]   [Full Text] [Related]  

  • 8. Remarkable progress toward new treatments for cystic fibrosis.
    Eldredge LC; Ramsey BW
    Lancet Respir Med; 2014 Dec; 2(12):962-4. PubMed ID: 25466347
    [No Abstract]   [Full Text] [Related]  

  • 9. Excitement mounts for first disease-modifying cystic fibrosis drugs.
    Opar A
    Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393
    [No Abstract]   [Full Text] [Related]  

  • 10. Ivacaftor in a young boy with the rare gating mutation S549R--use of lung clearance index to track progress: a case report.
    Lenherr N; Lurà M; Trachsel D; Latzin P; Hammer J
    BMC Pulm Med; 2015 Oct; 15():123. PubMed ID: 26474553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting a cystic fibrosis mutation opens door for personalized treatment.
    Morrow T
    Manag Care; 2012 Apr; 21(4):53-4. PubMed ID: 22590787
    [No Abstract]   [Full Text] [Related]  

  • 12. Mutation-specific therapy in cystic fibrosis: the earlier, the better.
    Tümmler B
    Lancet Respir Med; 2013 Oct; 1(8):591-592. PubMed ID: 24461654
    [No Abstract]   [Full Text] [Related]  

  • 13. Personalized medicine. New cystic fibrosis drug offers hope, at a price.
    Kaiser J
    Science; 2012 Feb; 335(6069):645. PubMed ID: 22323790
    [No Abstract]   [Full Text] [Related]  

  • 14. Potentiators for cystic fibrosis - targeting the underlying molecular defect.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Paediatr Respir Rev; 2015 Jun; 16(3):162-4. PubMed ID: 26002404
    [No Abstract]   [Full Text] [Related]  

  • 15. Update in cystic fibrosis 2013.
    Jain M; Goss CH
    Am J Respir Crit Care Med; 2014 May; 189(10):1181-6. PubMed ID: 24832742
    [No Abstract]   [Full Text] [Related]  

  • 16. A combination therapy for cystic fibrosis.
    Brodsky JL; Frizzell RA
    Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sweat chloride is not a useful marker of clinical response to Ivacaftor.
    Barry PJ; Jones AM; Webb AK; Horsley AR
    Thorax; 2014 Jun; 69(6):586-7. PubMed ID: 24258833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized medicine comes to cystic fibrosis.
    Am J Med Genet A; 2012 Feb; 158A(2):viii-ix. PubMed ID: 22266959
    [No Abstract]   [Full Text] [Related]  

  • 19. Update in Cystic Fibrosis 2014.
    Ong T; Ramsey BW
    Am J Respir Crit Care Med; 2015 Sep; 192(6):669-75. PubMed ID: 26371812
    [No Abstract]   [Full Text] [Related]  

  • 20. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.